{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:53:12Z","timestamp":1793681592000,"version":"4.5.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.msard.2022.104485","type":"journal-article","created":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T22:01:10Z","timestamp":1671919270000},"page":"104485","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Barriers to access and unmet needs to neuromyelitis optica spectrum disorders care in an Argentinean cohort"],"prefix":"10.1016","volume":"70","author":[{"given":"Ver\u00f3nica","family":"Tkachuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Eugenia","family":"Balbuena Aguirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Barboza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana del Valle","family":"Liwacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Mainella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan I.","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berenice Anabel","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dar\u00edo","family":"Tavolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"Zanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Delgado Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7435-5726","authenticated-orcid":false,"given":"Edgar","family":"Carnero Contentti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.msard.2022.104485_bib0001","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/ana.25411","article-title":"Brain and cord imaging features in neuromyelitis optica spectrum disorders","volume":"85","author":"Cacciaguerra","year":"2019","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2022.104485_bib0002","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies","volume":"18","author":"Carnero Contentti","year":"2021","journal-title":"J. Neuroinflammat."},{"key":"10.1016\/j.msard.2022.104485_bib0003","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.msard.2017.11.004","article-title":"Frequency of brain MRI abnormalities in neuromyelitis optica spectrum disorder at presentation: A cohort of Latin American patients","volume":"19","author":"Carnero Contentti","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2022.104485_bib0004","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1352458519898590","article-title":"Barriers to access and utilization of multiple sclerosis care services in a large cohort of Latin American patients","volume":"27","author":"Carnero Contentti","year":"2021","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2022.104485_bib0005","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/14728214.2022.2059463","article-title":"Emerging drugs for the acute treatment of relapses in adult neuromyelitis optica spectrum disorder patients","volume":"27","author":"Carnero Contentti","year":"2022","journal-title":"Expert. Opin. Emerg. Drugs"},{"key":"10.1016\/j.msard.2022.104485_bib0006","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.msard.2019.05.024","article-title":"Access and unmet needs to multiple sclerosis care in a cohort of Argentinean patients","volume":"33","author":"Carnero Contentti","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104485_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103026","article-title":"Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice[Mult Scler Relat Disord. 2020 Oct;45:102428]","volume":"52","author":"Carnero Contentti","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104485_bib0008","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.msard.2018.01.001","article-title":"Application of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of Latin American patients","volume":"20","author":"Carnero Contentti","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2022.104485_bib0009","article-title":"Assessing attacks and treatment response rates among adult patients with NMOSD and MOGAD: data from a nationwide registry in Argentina","volume":"7","author":"Contentti","year":"2021","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"10206","key":"10.1016\/j.msard.2022.104485_bib0010","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"N-MOmentum study investigators. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2022.104485_bib0011","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jns.2018.01.004","article-title":"Argentinean recommendations on the identification of treatment failure in relapsing remitting multiple sclerosis patients","volume":"385","author":"Cristiano","year":"2018","journal-title":"J. Neurol. Sci."},{"issue":"7","key":"10.1016\/j.msard.2022.104485_bib0012","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1177\/1352458512462918","article-title":"The epidemiology of multiple sclerosis in Latin America and the Caribbean: a systematic review","volume":"19","author":"Cristiano","year":"2013","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104485_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.966428","article-title":"The patient journey with NMOSD: from initial diagnosis to chronic condition","volume":"13","author":"Delgado-Garcia","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2022.104485_bib0014","article-title":"Burden and cost of comorbidities in patients with neuromyelitis optica spectrum disorder","volume":"427","author":"Exuzides","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2022.104485_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102967","article-title":"Socioeconomic status and access to multiple sclerosis treatment in Mexico","volume":"52","author":"G\u00f3mez-Figueroa","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104485_bib0016","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.msard.2019.05.013","article-title":"Neuromyelitis optica testing and treatment: availability and affordability in 60 countries","volume":"33","author":"Holroyd","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2022.104485_bib0017","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13023-022-02310-z","article-title":"Health utilities and costs for neuromyelitis optica spectrum disorder","volume":"17","author":"Hughes","year":"2022","journal-title":"Orphanet. J. Rare. Dis."},{"issue":"11","key":"10.1016\/j.msard.2022.104485_bib0018","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1212\/WNL.0000000000001367","article-title":"Guthy-Jackson Charitable Foundation NMO International Clinical Consortium & Biorepository. MRI characteristics of neuromyelitis optica spectrum disorder: an international update","volume":"84","author":"Kim","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2022.104485_bib0019","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40120-021-00311-x","article-title":"Evaluating the economic burden of relapses in neuromyelitis optica spectrum disorder: a real-world analysis using German claims data","volume":"11","author":"Knapp","year":"2022","journal-title":"Neurol. Ther."},{"issue":"11","key":"10.1016\/j.msard.2022.104485_bib0020","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2022.104485_bib0021","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1474-4422(20)30392-6","article-title":"New therapies for neuromyelitis optica spectrum disorder","volume":"20","author":"Levy","year":"2021","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.msard.2022.104485_bib0022","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.msard.2022.104485_bib0023","article-title":"Access and barriers to MS care in Latin America","volume":"3","author":"Rivera","year":"2017","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2022.104485_bib0024","first-page":"1","article-title":"Multiple sclerosis and neuromyelitis optica spectrum disorder testing and treatment availability in Latin America","author":"Rojas","year":"2021","journal-title":"Neurol. Res."},{"issue":"2","key":"10.1016\/j.msard.2022.104485_bib0025","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s40120-021-00253-4","article-title":"Neuromyelitis Optica Spectrum Disorder: Clinical Burden and Cost of Relapses and Disease-Related Care in US Clinical Practice","volume":"10","author":"Royston","year":"2021","journal-title":"Neurol. Ther."},{"issue":"5","key":"10.1016\/j.msard.2022.104485_bib0026","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2022.104485_bib0027","article-title":"Status of the neuromyelitis optica spectrum disorder in Latin America","volume":"53","author":"VM","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2022.104485_bib0028","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1212\/NXI.0000000000000089","article-title":"MOG cell-based assay detects non-MS patients with inflammatory neurologic disease","volume":"2","author":"Waters","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.msard.2022.104485_bib0029","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"Weinshenker BG; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.msard.2022.104485_bib0030","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMra1904655","article-title":"Neuromyelitis optica spectrum disorder","volume":"387","author":"Wingerchuk","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.msard.2022.104485_bib0031","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of Satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822009890?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822009890?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:05:02Z","timestamp":1761901502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822009890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":31,"alternative-id":["S2211034822009890"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.104485","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Barriers to access and unmet needs to neuromyelitis optica spectrum disorders care in an Argentinean cohort","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.104485","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104485"}}